Bicycle Therapeutics Plc

  • Moat Score
  • Market Cap $525.20M
  • PE -3
  • Debt -
  • Cash $793.52M
  • EV -
  • FCF -$182.05M

Earnings

loading chart...

Sales & Net Margins

loading chart...
Earnings-$203.22M
EBIT-$208.72M
ROE-27%
ROA-24%
FCF-$182.05M
Equity$740.33M
Growth Stability1
PE-2.58
PB0.71
P/FCF-2.88
P/S20.42
Price/Cash1.51
Net Margins-609%
Op. Margins-811%
Sales Growth YoY-49%
Sales Growth QoQ169%
Sales CAGR23%
Equity CAGR49%
Earnings Growth YoY129%
Earnings Growth QoQ17%
Sales CAGR 5Y33%
Equity CAGR 5Y57%
Earnings CAGR 3Y67%
Sales CAGR 3Y67%
Equity CAGR 3Y61%
Market Cap$525.20M
Revenue$25.72M
Assets$883.89M
Cash$793.52M
Shares Outstanding69.2M
Moat Score1%
Working Capital798.46M
Current Ratio14.86
Shares Growth 3y38%
Equity Growth QoQ-7%
Equity Growth YoY108%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops which stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical need.

SEC Filings

Direct access to Bicycle Therapeutics Plc (BCYC) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

  • 2025
    • 10-Q Mar 31
  • 2024
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2023
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31

Sector Comparison

How does Bicycle Therapeutics Plc compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Bicycle Therapeutics Plc compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Bicycle Therapeutics Plc Discounted Cash Flow

Fully customizable DCF calculator online for Bicycle Therapeutics Plc.

= -$1.8B
012345678910TV
fcf-$182M-$182M-$182M-$182M-$182M-$182M-$182M-$182M-$182M-$182M-$182M-$1.8B
DCF-$166M-$150M-$137M-$124M-$113M-$103M-$93M-$85M-$77M-$70M-$702M
Value-$1.8B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years12/201712/201812/201912/202012/202112/202212/202312/2024TTM
Net Margins-789%-306%-222%-491%-571%-779%-670%-479%-609%
ROA--27%-24%-32%-14%-28%-30%-18%-24%
ROE-31%-33%-53%-19%-42%-49%-21%-27%

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years12/201712/201812/201912/202012/202112/202212/202312/2024TTM
Debt over FCF----0.79-1.78-0.29-0.48--
Debt over Equity---0.160.090.110.08--
Growth Stability--------1

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years12/201712/201812/201912/202012/202112/202212/202312/2024CAGR 5Y
Revenue YoY growth-246%93%-25%13%24%87%31%33%
Earnings YoY growth-34%40%67%31%69%60%-6%-
Equity YoY growth-48%-233%2%263%-22%37%114%57%
FCF YoY growth-978%11%-37%-11%525%-40%161%-